• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

ProZinc now approved for use in dogs

February 12, 2019
dvm360 Staff
dvm360, dvm360 March 2019, Volume 50, Issue 3

Veterinary product from Boehringer Ingelheim becomes second approved insulin for use in canine diabetes cases.

Nearly a decade ago, ProZinc (protamine zinc recombinant human insulin) was approved by the FDA for the reduction of hyperglycemia and associated clinical signs in cats with diabetes mellitus. Last week, the FDA announced that the product is now approved for use in dogs as well, making it the second approved product available to veterinarians for managing canine diabetes. Vetsulin (porcine insulin zinc suspension), manufactured by Merck Animal Health, is the other.

Available by prescription only, ProZinc is packaged in 10-ml multidose vials at a concentration of 40 IU/ml. It is administered via subcutaneous injection using a U-40 syringe, according to an FDA release. The recommended starting dose in dogs is 0.2 to 0.5 IU/pound of body weight (0.5-1.0 IU/kg) once daily. The starting dose for cats is 0.1 to 0.3 IU/pound (0.2-0.7 IU/kg) given twice daily. In both species, the drug should be given with or just after a meal.

The FDA says that because compounded drugs vary in quality and potency, it strongly encourages the use of FDA-approved veterinary insulin for newly diagnosed diabetic dogs or when transitioning patients from one product to another.

Advertisement

Pets given any insulin product should be re-evaluated at appropriate intervals with the dose and frequency adjusted as needed based on clinical signs and laboratory parameters until adequate glycemic control has been attained.

ProZinc is contraindicated in dogs and cats that are sensitive to protamine zinc recombinant human insulin or any other ingredients in ProZinc, according to the FDA. The drug should not be given during episodes of hypoglycemia. The most common adverse effects in the canine clinical trial were lethargy, anorexia, hypoglycemia, vomiting, seizures, shaking, diarrhea and ataxia.

download issueDownload Issue: dvm360 March 2019

Related Content:

MedicalProductsBreaking NewsEndocrinologydvm360 March 2019
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement